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Accuracy of a Flash Glucose Monitoring System in Diabetic Dogs
S. Corradini, B. Pilosio, F. Dondi, G. Linari, S. Testa, F. Brugnoli, P. Gianella, M. Pietra, and
F. Fracassi
Background: A novel flash glucose monitoring system (FGMS) (FreeStyle Libre, Abbott, UK) was recently developed for
humans. It continuously measures the interstitial glucose (IG) concentrations for 14 days.
Objectives: To assess the clinical and analytical accuracy of the FGMS in diabetic dogs.
Animals: Ten client-owned diabetic dogs on insulin treatment.
Methods: Prospective and observational study. The FGMS was placed on the neck for up to 14 days. During the 1st–
2nd, 6–7th, and 13–14th days from application, the IG measurements were compared with the plasma (EDTA) glucose (PG)
concentrations analyzed by a reference hexokinase based method.
Results: The application and the use of the FGMS were apparently painless, easy, and well tolerated by all dogs. Mild
erythema at the site of the application was found in 5/10 dogs at the end of the wearing period. A good correlation between
IG and PG concentrations (rho = 0.94; P < .001) was found. The FGMS was 93, 99, and 99% accurate at low, normal, and
high blood glucose concentrations. Mean  standard deviation difference from the reference method was 2.3  46.8 mg/dL.
Conclusion and clinical importance: The FGMS is easy to use and is accurate for IG glucose measurement in diabetic
dogs.
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Glycemic control is a cornerstone for the manage-ment of diabetes mellitus (DM) in human and vet-
erinary medicine. Self-monitoring blood glucose system
and continuous glucose monitoring systems (CGMS)
are routinely used in human diabetic patients. Different
systems for real-time CGMS have been available for the
use in human diabetic patients and many publications
support the clinical benefit of the CGMS.1
In diabetic dogs, the evaluation of blood glucose
curves (BGCs) allows the clinician to determine if the
insulin administered is effective and identify the glucose
nadir, time of peak insulin effect, duration of insulin
effect, and degree of fluctuation in blood glucose con-
centrations in that particular dog. To perform a BGC,
the diabetic dog is generally hospitalized for 10–
12 hours and the capillary blood glucose concentration
is usually measured every 2 hours. Nowadays, some
owners are able to perform home monitoring by mea-
suring the capillary blood glucose concentrations using
a portable blood glucose meter (PBGM). The main lim-
itations of the BGCs interpretation include the require-
ment of numerous capillary drops of blood that in
some dogs can be difficult to obtain and become a
source of stress; nevertheless, the glucose nadir or peak
can be missed measuring the blood glucose concentra-
tion every 2 hours. Moreover, the BCGs in the hospital
are time consuming and expensive.
The use of CGMS has been already described in vet-
erinary medicine,2–9 even though the devices used in
previous studies have a number of limitations and are
not commonly used clinically. The CGMS can measure
the IG concentrations in the subcutaneous interstitial
fluid. Such devices typically consist of a sensor that is
applied on the surface of the body to measure glucose
concentrations and a transmitter by which the glucose
data are displayed. The first generation systems offered
only retrospective analysis of the glucose concentrations
after disconnecting the sensor and uploading the data,
whereas the newest generation measure and display the
data immediately, allowing direct intervention (real-time
CGMS).10 However, the main shortcoming of most
CGMSs is that they need to be calibrated and therefore
capillary blood sampling is required.9,10
A novel flash glucose monitoring system (FGMSa )
has been licensed recently for the use in the European
Union (CE mark August 2014). The FGMS measures
interstitial tissue (IG) glucose levels every minute via a
disposable round sensor with a small catheter inserted
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under the skin that can be worn for up to 14 days. This
FGMS is factory-calibrated and does not require finger-
stick blood glucose measurements for calibration. It is
designed for human diabetic patients to replace blood
glucose monitoring and for use in day-to-day treatment
decisions.
The present study evaluates the analytical and clinical
accuracy of the FGMS in diabetic dogs.
Materials and Methods
Dogs
Ten client-owned diabetic dogs were enrolled in the study. All
dogs were diagnosed with DM and they were on insulin treatment
for at least 1 month. Seven were neutered females and 3 were
males (2 castrated). Breeds included mixed breed (4 dogs), Dachs-
bracke (1), English Setter (1), Epagneul Breton (1), Toy Poodle
(1), Springer Spaniel (1), and Yugoslavian Shepherd dog (1). The
median age was 9.5 years (range 2–13) and the median body
weight was 18.0 kg (5.4–43.0 kg). Seven dogs were treated with
porcine insulin zinc suspension,b 2 with glargine,c and 1 with Neu-
tral Protamine Hagedorn (NPH) human analog insulin.d All dogs
did not have any concurrent disease and did not receive any other
drugs during the study period. The protocol and informed consent
forms were approved by the Scientific Ethics Committee of the
University of Bologna. The recruitment of dogs in the study was
voluntary and at no cost to the owners. Written informed consent
before enrollment in the study was obtained.
Flash Glucose Monitoring System
The flash glucose monitoring system,a FreeStyle Libre is com-
posed of a small round sensor (35 mm 9 5 mm). The sensor has a
small catheter (0.4 mm 9 5 mm) inserted under the skin through
which the sensor can measure the IG concentration. It can be
worn for up to 14 days and is water resistant. The sensor is
applied on the skin easily and intuitively by the applicator fur-
nished by the manufacturer.
The sensor is based on the glucose-oxidase method, which mea-
sures an electrical current proportional to the glucose concentra-
tion. The electrode has a long carbon chain that holds both
glucose oxidase and an osmium mediator, called a “wired
enzyme”. After glucose has reduced by the glucose oxidase, the
enzyme passes its electrons to the osmium mediator rather than
oxygen. The mediator then passes the electrons to the electrode
for measurement, this avoids using oxygen and thus the require-
ment for a limiting membrane on the sensor.11,12 The detection
limits of the sensor are between 20 and 500 mg/dL; however, the
readings beyond this range are not recorded. The system starts
working 1 hour from application (Fig 1).
This system is factory calibrated, so it does not require any cal-
ibration before and during the wearing period. Measuring blood
glucose and correlating it to the sensor current at one point in
time determines the calibration factor. The sensor has to be
scanned by the reader and in 1 second the reader can show
instantaneously the glucose reading. The FGMS generates infor-
mation every minute and the readings, day and night, are col-
lected, registered, and stored automatically. An USB port on the
reader can be used to charge it and to download all data on a
computer. The software used by the FGMS generates different
reports from the uploaded sensor data. Moreover, the reader con-
tains a port that can be used with a test strip for built-in blood
glucose and ketone meters. At the end of wearing period, the sen-
sor is fully disposable but the reader can be re-used for a new
sensor. In this study, a single sensor was placed in a clipped and
sterile area (5 cm 9 5 cm) on the neck of each diabetic dog
(Fig 2A). After positioning, the sensor was fixed with extra tape
and a body bandage was used to secure the sensor at the body
(Fig 2B–C). At the end of wearing period all dogs were judged
subjectively for the presence of erythema by the same clinician
(SC).
Accuracy of FGMS
To compare the glucose readings measured with FGMS to the
reference method (hexokinase method), paired samples were col-
lected and then classified in the hypoglycemic (<70 mg/dL), in the
euglycemic range (70–180 mg/dL), and in the hyperglycemic range
(>180 mg/dL). All the values above and below the detection limit
of the sensor (≤20 and ≥500 mg/dL) were excluded (Fig 3).
During the wearing period of the sensor, each dog was evalu-
ated for 3-time periods as follows: from the 1st to 2nd day, from
the 6 to 7th, and from the 13 to 14th day. During every evaluation
period, that lasts 36 hours, blood samples were collected simulta-
neously every 2–3 hours from cephalic intravenous catheter previ-
ously placed. Mean (SD) number of samples, obtained during the
1st–2nd, 6–7th, 13–14th were 16.5 (12.4), 17.8 (6.5), and 16.6 (4.0)
respectively.
Fig 1. FreeStyle Libre FGMS is composed of the following: (A) the reader that in one-second shows the glucose reading; (B) the sensor
that with a small catheter measures the interstitial blood glucose in the subcutaneous tissue; and (C) the sensor is applied on the skin by
the provided applicator.
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During every sampling 0.5 mL of venous whole blood were col-
lected from each dog in a plasma EDTA tube and immediately
centrifuged for the analysis of peripheral venous glucose (PG) by
the hexokinase method. This was considered the reference method
and for this purpose an automated chemistry analyser,e ,f routinely
monitored with a robust QA program, was used.
Additionally, 0.6 lL of whole blood were used to measure
the glucose with a portable blood glucose meter (PBGM), the
Accu-Check Aviva NANO,g a PBGM that has been recently
evaluated.13 Simultaneously, within 1 minute from the sampling, it
also scanned the FreeStyle Libre on the sensor and all data were
registered.
The readings of FGMS were compared with those of the hexok-
inase method used as a reference.
To assess clinical accuracy the ISO 15197:2013 requirementsh
were used in accordance with the blood-glucose monitoring system
and shall meet both the following minimum criteria for acceptable
system accuracy: (1) 95% of the measured glucose values shall fall
within either 15 mg/dL of the average measured values of the
reference measurement procedure at glucose concentrations <100 mg/
dL or within 15% at glucose concentrations ≥100 mg/dL; and
(2) 99% of individual glucose measured values shall fall within
zones A and B of the Parkes Consensus Error Grid analysis14
(Consensus EGA) for type 1 DM. Consensus for the EGA sys-
tem was performed to assess clinical risks for each measurement
and assigned on the x axis the values of glucose concentrations
measured by the reference method versus the values of glucose
concentrations measured by FGMS on the y axis to 8 concentric
zones with no discontinuities (A through E) defined by different
lines.14
Data Analysis
Normality was assessed with the Shapiro–Wilk test and non-
parametric tests were used accordingly.
Correlation between the IG measured by FGMS and PG mea-
sured by the hexokinase method was evaluated with Spearman’s
rank correlation. The differences between IG and the PG were
plotted against the reference values in Bland–Altman plots. The
differences between the PG measured by the hexokinase method
and glucose measured by the PBGM were plotted against the
reference values in Bland–Altman plots.
A B C
Fig 2. (A) The sensor is applied on the neck of the dog; (B) with extra-tape to secure it on the skin surface; and (C) a bandage was used
as an additional security.
Fig 3. Bland–Altman plots represent the differences between blood glucose concentrations obtained by the use of FGMS versus the refer-
ence method (hexokinase). (A) the values obtained by the use of FGMS and the PBGM (Accu-Check Aviva Nano); and (B) including all
samples for ISO15197: 2013. On the x-axis are, the reference glucose values plotted against the absolute errors for each corresponding
value. The standard required limits defined by the gray symmetric lines: at 15 mg/dL from the reference value for glucose determinations
<100 mg/dL and at 15% from the reference for glucose ≥100 mg/dL. Percentages express the number of samples within limits when refer-
ence was < or ≥100 mg/dL and for the total number of measurements (central% value).
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The Friedman 2-way ANOVA was used to compare the
differences between IG and the PG in the 3-time periods. The
Mann–Whitney test evaluated the interference by the presence of
inflammation at the site of application. Statistical analysis was
performed with the aid of commercially available software.i,j Differ-
ences were considered significant at P < .05.
Results
Practical Use of the FGMS
The application and use of the FreeStyle Libre were
painless, easy, and well-tolerated by all dogs. In all
dogs, the sensor read the IG concentrations after
60 minutes from application. In 7/10 dogs, the sensor
lasted for 14 days, although in 3/10 the sensor stopped
to record interstitial glucose before the end of the study
because it was accidentally detached from the dog’s
skin. At the end of the study 5/10 dogs showed mild
erythema at the site of application of the sensor and 1
dog had bent the needle. The FGMS was able to detect
all the interstitial glucose fluctuations (because of insu-
lin treatment and food administration) when they were
within the detection limits of the instrument. Rapid
changes of glucose concentrations like in the Somogyi
effect were not detected during the study.
Accuracy of the FGMS
Four hundred thirty-two paired samples were taken.
Based on the reference method (hexokinase), 7% (29/
432) of samples were in the hypoglycemic range with a
median glucose concentration (min–max) of 54 mg/dL
(37–69); 40% (173/432) of samples were in the eug-
lycemic range with a median glucose concentration of
96 mg/dL (72–180); and 53% (230/432) of samples were
in the hyperglycemic range with a median glucose con-
centration of 327 mg/dL (183–625).
Forty percent (173/432) of samples were collected in
the first time period, 33% (143/432) of samples were
collected in the second time period, and 27% (116/432)
during the last time period. Considering all methods,
hexokinase, FGMS, and PBGM, the median glucose
concentrations (min–max) were 198 mg/dL (37–625),
205 mg/dL (40–495), and 179 mg/dL (28–600) respec-
tively. The median difference (min–max) between the
IG measured by the FGMS and hexokinase method
was 5 mg/dL (385–309 mg/dL); instead, the median
difference between the PBGM and the hexokinase
method was 17 mg/dL (123–70 mg/dL).
Correlation between the IG measured by the FGMS
and the peripheral glucose measured by the exochinase
method with rho = 0.94. The correlation coefficient value
decreased considering only the samples in the hypo-
glycemic (R = 0.43, P < .001), euglycemic (R = 0.50,
P = .018), and hyperglycemic (R = 0.85, P < .001)
ranges. Moreover, the median individual correlation was
rho = 0.85 (0.22–0.98). Considering all samples, the
mean differences in the glucose concentrations (mean;
SD) obtained with the FGMS compared to the reference
method and the readings obtained by the PBGM com-
pared to the reference method were 2.3;46.8 and
21.2;23.7 mg/dL respectively (Fig 3). When evaluating
the different glycemic intervals, the mean differences in
the glucose concentrations obtained with FGMS com-
pared with the reference method were 1.1;15.4, 6.0;19.7
and 4.0;46.8 mg/dL for the hypoglycemic, euglycemic,
and hyperglycemic ranges respectively. The percentage of
overestimated glucose readings was higher than the
underestimate values at normal (54% versus 44%) and
high (59% versus 40%) glucose concentrations; con-
versely, in the hypoglycemic range, compared to the over-
estimated readings, the underestimated readings were
higher (69% versus 31%).
Considering the ISO 15197:2013 requirements for
FGMS when compared with the hexokinase method,
68% of values of total measurement are within the lim-
its (Fig 3A); however, for PBGM compared with the
hexokinase method, 72% of measurements are within
the limits (Fig 3B).
Regarding the Consensus EGA, considering all the
samples, with FGMS the 99% of the samples fall in the
zone A+B. Considering the three subgroups in the hypo-
glycemic range only the 93% of the samples fall in zone
A+B, in the euglycemic range 99% of the values fall in
zone A+B, and in the hyperglycemic range 99% of sam-
ples fall in zone A+B. Considering the accuracy over
time, we found a significant decrease of the mean differ-
ence (mg/dL) of glucose concentrations during the wear-
ing period. Such difference was significant between the
1st–2nd (12.54 mg/dL) and the 6–7th (10.36 mg/dL) days
(P < .05), and between the 6–7th (10.36 mg/dL) and 13–
14th (14.07 mg/dL) days (P < .05). Considering only the
last time period, a decrease of the mean difference was
found in dogs with mild inflammation when compared
with dogs without inflammation (34.39 mg/dL versus
11.42 mg/dL) at the end of the study period.
Discussion
The use of the FGMS resulted in the accurate mea-
surement of IG in diabetic dogs.
The utilization of FGMS is new in human diabetic
patients and a single study is available.15 In this study,
the IG measurements with the FGMS system were
accurate compared with capillary BG reference values
with accuracy remaining stable over 14 days of wear-
able technology and unaffected by patient characteris-
tics.15
The application of the sensor on the neck of dogs
was quick, simple, painless, and intuitive because of the
applicator provided within the device package. The site
of the positioning of the sensor on the neck was chosen
for convenience, because it was easy to secure with a
bandage on the body of the dog. After application, the
sensor has 1-hour period of initialization and in all dog
the sensor read the IG concentrations after 60 minutes
from application as reported by the manufacturer. At
the end of the wearing period, in 5/10 dogs a mild ery-
thema was noted at the site of the application of the
sensor and 1 dog had bent needle, but all dogs tolerated
well the use of a bandage. The presence of mild ery-
thema probably could be related to the removal of the
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patch that surrounds the sensor. In all dogs, the mild
erythema disappeared spontaneously after 24 hours
from the detachment of the sensor. Similar skin lesions
were observed in human diabetic patients and there was
moderate to severe itching in 0.5% of the cases and
moderate erythema in 4% of cases.15 In one case, there
was bent needle and this could be related to individual
attitude of the dog or a deficiency to secure the sensor
at the body of the dog.
In Davison2 et al, a good correlation between the IG
and PG was found with R = 0.81; however, in our
study we found a correlation of rho = 0.94. The
correlations were lower considering the samples in the
hypoglycemic, euglycemic, and hyperglycemic ranges,
respectively; this was an expected occurrence because of
a smaller sample size in each subgroup. The median
individual correlation between IG and PG in each single
dog decreased (rho = 0.85), which could be related to
the detachment of the sensor from the dog’s skin or
probably because of individual characteristics of the
skin such as increasing thickness. It is possible that the
skin thickness has an influence in the performance of
the sensor. However, in the present study, only dogs
without concurrent disorders such as hypothyroidism,
hyperadrenocorticism, or pyoderma that could alter the
thickness of the skin or the blood flow, were included.
In human medicine an increasing clinical accuracy for
the system, FreeStyle Navigator was found for partici-
pants who had a body mass index (BMI) >30 kg/m2
compared to participants with BMI of <25 kg/m2. This
finding has been attributed to differences in blood flow
relative to subcutaneous adipose tissue thickness.16 Con-
versely, another recent study that evaluated the FGMS
did not find any correlation with BMI.15
Flash glucose monitoring system is the unique among
existing IG monitoring technologies in that the wired
enzyme factory-calibrated sensor has a wear time of up
to 14 days without additional calibrations.15,17 The
results of our study evaluated an agreement between the
FGMS and the reference method (hexokinase), which
shows a minimal mean difference (2.3 mg/dL, SD 46.8)
for the glucose readings. We compared the PG mea-
sured by the reference method and by a PBGM that
represents a glucometer approved for humans and
recently evaluated as one of the best glucometers for
dogs to obtain a further direct comparison between
FGMS and PBGM.13 In our study, we found a mean
difference of 21.2 mg/dL (SD 23.7) for PBGM com-
pared to the reference method, which is in agreement
with a pervious study.13
The mean difference of IG compared with the refer-
ence method was minimal in the 3 subgroups, hypo-
glycemic, euglycemic, and hyperglycemic ranges. The
results of the Consensus EGA showed acceptable clini-
cal accuracy in the euglycemic and hyperglycemic
ranges with 99% of reading fallen in zone A+B. In the
hypoglycemic level, the clinical accuracy decreased
slightly with 93% of readings in zone A+B.
During the wearing period, we found a significant
decreased of the mean difference between 1st and 2nd
days when compared to 13–14th days and between the
6–7th days compared to 13–14th days. This is in con-
trast with other studies that previously published as
regards human diabetic patients where the accuracy of
the CGMS decreased from the 1st day from applica-
tion. This is due in part to the inflammatory responses
to sensor insertion, which affect glucose concentrations
in interstitial fluid.18 A decreased mean difference was
found in the dogs with mild inflammation (34.39 mg/
dL versus 11.42 mg/dL) at the end of the wearing per-
iod, which could be related to the inflammation present
at the site of application. Likewise, the presence of
inflammation could affect the site of application.
Flash glucose monitoring system provides a broad
and wide interval and numbers of readings during a 24-
hour period and can be used to evaluate glucose pat-
terns and trends. The hand-held reader displaces the
previous 8-hour history but with a maximum upper
range of 350 mg/dL. This range is appropriate for
human diabetic patients where an intensive glycemic
control is usually the goal of the treatment but not ideal
in dogs where a wider range of glucose values is consid-
ered acceptable.
The limitations of the current study include that a
single sensor was used in each dogs; therefore, the preci-
sion of the FGMS was not investigated. The time of
Fig 4. Parkes Consensus error grid analysis for the values obtained by FGMS and the representation with the percentage of values within
A+B zones. The reference glucose values on the x-axis are plotted against the blood glucose by the glucose meter (y-axis). The different
zones designate the magnitude of risk derived from the determination: no effect on clinical action (zone A), altered clinical action: little or
no effect on clinical outcome (zone B), altered clinical action: likely to affect clinical outcome (zone C), altered clinical action: could have
significant medical risk (zone D), and altered clinical action could have dangerous consequences (zone E) (Parkes et al,14).
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delay between the IG and PG is usually investigated by
injecting a bolus of dextrose IV and then subsequently
measuring the IG and PG in the subsequent minutes.
This procedure was performed on some of the dogs in
our study (data not showed), but FGMS was unable to
measure the rapid changes between the PG and IG.
Another limitation is that the thickness of the skin at
the site of application of the sensor has not been evalu-
ated.
The novel FGMS was accurate to evaluate IG when
compared to the reference method. Flash glucose moni-
toring system could be a valid alternative for glucose
monitoring in diabetic dogs because it has a small and
comfortable sensor, allows for easy and quick glucose
monitoring, calibrations are requested during the wear-
ing period, and the sensor lasts up to 14 days.
Despite the ISO 2013 requirements were partially
unfulfilled in our study, FGMS seems accurate to
evaluate the PG in diabetic dogs with less clinical accu-
racy in the hypoglycemic range. Further studies are
necessary to evaluate the clinical use of FGMS in the
long-term monitoring of diabetic dogs and especially its
ability to detect hypoglycemic events and the Somogyi
phenomena.
Footnotes
a FreeStyle Libre, Abbott, UK
b Caninsulin, Intervet International BV, Boxmeer, The
Netherlands
c Lantus, Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt
am Main, Germany
d Humulin I, Eli Lilly Italia S.p.A., 50019 Sesto Fiorentino (FI) -
Italia
e AU400; Beckman-Coulter/Olympus, O’Callaghan’s Mills, Ireland
f Glucose OSR 6121; Beckman-Coulter/Olympus
g Accu-check Aviva Nano, Roche Diagnostics S.p.A., Monza
(MI), Italy
h BSI Standards Publication, In vitro diagnostic test systems –
Requirements for blood-glucose monitoring systems for self-test-
ing in managing diabetes mellitus (EN ISO 15197:2013).
i Prism version 5.0d, GraphPad software Inc, San Diego, CA
j R Core Team (2013). R: A language and environment for statisti-
cal computing. R Foundation for Statistical Computing, Vienna,
Austria. URL http://www.R-project.org/
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